These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

889 related items for PubMed ID: 31005275

  • 1. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D.
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [Abstract] [Full Text] [Related]

  • 2. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C.
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [Abstract] [Full Text] [Related]

  • 3. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H, Kim JI, Moon IS, Chung BH, Yang CW, Kim Y, Han K, Oh EJ.
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK, Llorente S, Martinez-Garcia P, Alfaro R, Jimenez-Coll V, Boix F, Galián JA, Martinez-Banaclocha H, Botella C, Moya-Quiles MR, Minguela A, Legaz I, Muro M.
    Curr Protein Pept Sci; 2021 May; 22(10):745-757. PubMed ID: 34967284
    [Abstract] [Full Text] [Related]

  • 6. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW, Lee H, Choi BS, Park CW, Yang CW, Kim YS, Choi YJ, Oh EJ, Chung BH.
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M, Boratyńska M, Kościelska-Kasprzak K, Kamińska D, Bartoszek D, Zabińska M, Myszka M, Zmonarski S, Protasiewicz M, Nowakowska B, Hałoń A, Chudoba P, Klinger M.
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [Abstract] [Full Text] [Related]

  • 9. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A, Süsal C, Schröder C, Höcker B, Rieger S, Waldherr R, Westhoff JH, Sander A, Dragun D, Tönshoff B.
    Nephrol Dial Transplant; 2018 Jun 01; 33(6):1065-1072. PubMed ID: 29444269
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
    Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.
    J Am Soc Nephrol; 2018 Feb 01; 29(2):620-635. PubMed ID: 29042454
    [Abstract] [Full Text] [Related]

  • 13. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M, Boratyńska M, Kościelska-Kasprzak K, Kamińska D, Zmonarski S, Mazanowska O, Krajewska M, Bartoszek D, Zabińska M, Myszka M, Kamińska M, Hałoń A, Dawiskiba T, Szyber P, Sas A, Klinger M.
    Transplant Proc; 2014 Oct 01; 46(8):2618-21. PubMed ID: 25380879
    [Abstract] [Full Text] [Related]

  • 14. Effect of angiotensin II type 1 receptor antibodies on graft function and survival in paediatric kidney transplant recipients.
    Kermond RF, Kim S, Mackie F, Hahn D, Carroll RP, Sharma A, Durkan AM.
    HLA; 2024 Sep 01; 104(3):e15649. PubMed ID: 39247998
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
    Cherukuri A, Mehta R, Sharma A, Sood P, Zeevi A, Tevar AD, Rothstein DM, Hariharan S.
    Kidney Int; 2019 Jul 01; 96(1):202-213. PubMed ID: 31029504
    [Abstract] [Full Text] [Related]

  • 16. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Nephrology (Carlton); 2019 Mar 01; 24(3):347-356. PubMed ID: 29451342
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H, Han E, Choi AR, Ban TH, Chung BH, Yang CW, Choi YJ, Oh EJ.
    PLoS One; 2018 Mar 01; 13(11):e0207434. PubMed ID: 30427941
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.